Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease

Thrombosis Research

Volumn 124, Issue 4, 2009, Pages 452-457

  Pawlak, Krystyna ^a   Domaniewski, Tomasz ^a   Mysliwiec, Michal ^a   Pawlak, Dariusz ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

End stage renal disease; Kynurenines; Oxidative status; Thrombomodulin; von Willebrnd factor

Indexed keywords

3 HYDROXYKYNURENINE; 3,4 METHYLENEDIOXYAMPHETAMINE; COPPER ZINC SUPEROXIDE DISMUTASE; ENOXAPARIN; KYNURENINE; KYNURENINE DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; QUINOLINIC ACID; THROMBOMODULIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DIALYSATE; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE DRUG DOSE; UREMIA;

BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KYNURENINE; MALE; MIDDLE AGED; OXIDATIVE STRESS; REPRODUCIBILITY OF RESULTS; THROMBOMODULIN; VON WILLEBRAND FACTOR;

EID: 69249229720     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.04.011     Document Type: Article

References (32)

1. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 suppl 3 (1998) S112-S119
2. Stenvinkel P., Pecoits-Filho R., and Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 14 (2003) 1927-1939
3. Vita J.A., and Keaney Jr. J.F. Endothelial function: a barometer for cardiovascular risk?. Circulation 106 (2002) 640-642
4. Jacobson S.H., Egberg N., Hylander B., and Lundahl J. Correlation between soluble markers of endothelial dysfunction in patients with renal feilure. Am J Nephrol 22 (2002) 42-47
5. Mezzano D., Pais E.O., Aranda E., Panes O., Downey P., Ortiz M., et al. Inflamation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 60 (2001) 1844-1850
6. Malyszko J., Malyszko J.S., and Mysliwiec M. Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis. Kidney Blood Press Res 27 (2004) 71-77
7. Pawlak K., Naumnik B., Brzósko S., Pawlak D., and Myśliwiec M. Oxidative stress-a link between endothelial injury, coagulation activation and atherosclerosis in haemodialysis patients. Am J Nephrol 24 (2004) 154-161
8. Pawlak K., Pawlak D., and Mysliwiec M. Long-term erythropoetin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. Thromb Res 120 (2007) 797-803
9. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P., et al. Endothelial cells in physiology and in the pathology of vascular disease. Blood 91 (1998) 3527-3561
10. Morange P.E., Simon C., Alessi M.C., Luc G., Arveiler D., Ferrieres J., et al. Endothelial cell markers and the risk of coronary heart disease. The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Circulation 109 (2004) 1343-1348
11. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., and van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Eng J Med 332 (1995) 635-641
12. Folsom A.R., Rosamond W.D., Shahar E., Cooper L.S., Aleksic N., Nieto F.J., et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 100 (1999) 736-742
13. Sadler J.E. Thrombomodulin structure and function. Thromb Haemost 78 (1997) 392-395
14. Blann A.D., Admiral J., and McCollum C.N. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol 59 (1997) 115-120
15. Blann A.D., and McCollum C.N. Von Willebrand factor and soluble thrombomoduin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinolysis 10 (1999) 375-380
16. Salomaa V., Matei C., Aleksic N., Sansores-Garcia L., Folsom A.R., Juneja H., et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 353 (1999) 1729-1734
17. Wu K.K. Soluble thrombomodulin and coronary heart disease. Curr Opin Lipidol 14 (2003) 373-375
18. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45 (1993) 309-379
19. Schroecksnadel K., Frick B., Winkler C., and Fusch D. Crucial role of interferon-γ and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 4 (2006) 205-213
20. Hansen A.M., Ball H.J., Miychell A.J., Miu J., Takikawa O., and Hunt N.H. Increased expression of indoleamine 2,3-dioxygenase in murine malaria infection is predominantly localized to the vascular endothelium. Int J Parasitol 34 (2004) 1309-1319
21. Stazka J., Luchowski P., Wielosz M., Klienrok Z., and Urbanska E.M. Endothelium-dependent production and liberation of kynurenic acid by rat aortic rings exposed to L-kynurenine. Eur J Pharmacol 448 (2002) 133-137
22. Pawlak D., Tankiewicz A., Mysliwiec P., and Buczko W. Tryptophan metabolizm via the kynurenine pathway in experimental chronic renal failure. Nephron 90 (2002) 328-335
23. Londero D., and Lo Greco P. Automated high-performance liquid chromatographic separation with spectrofluorometric detection of a malondialdehyde-tiobarbituric acid adduct in plasma. J Chromatogr A 729 (1996) 207-210
24. Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes Jr. D.R., and Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 (2000) 948-954
25. Pawlak D., Pawlak K., Malyszko J., Mysliwiec M., and Buczko W. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol 33 (2001) 399-404
26. Serradelli M., Diaz-Ricart M., Cases A., Zurbano M.J., Lopez-Pedret J., Arranz O., et al. Uremic medium causes expression, redistribution and shedding of adhesion molecules in cultured endothelial cells. Haematologica 87 (2002) 1053-1061
27. Zoccali C., Mallamaci F., and Tripepi G. Inflammation and atherosclerosis in end-stage renal disease. Blood Purif 21 (2003) 29-36
28. Okuda S., Nishiyama N., Saito H., and Katsuki H. 3-hydroxykynurenine, an endogenous oxidative stress generator, caused neuronal cell death with apoptotic features and region selectivity. J Neurochem 70 (1998) 299-307
29. Santamaria A., Flores-Escartin A., Martinez J.C., Osorio L., Galvan-Arzate S., Chaverri J.P., et al. Copper blocks quinolinic acid neurotoxicity in rats: contribution of antioxidant systems. Free Radic Biol Med 35 (2003) 418-427
30. Santamaria A., Salvatierra-Sanches, Vazquez-Roman B., Santiago-Lopez D., Villeda-Hernandez J., Galvan-Arzate S., et al. Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: in vitro and in vivo studies. J Neurochem 86 (2003) 479-488
31. Hoppenstead D., Faared J., Klein A.L., Jasper S.E., Apperson-Hansen C., Lieber E.A., et al. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation. Am J Cardiol 102 (2008) 842-846
32. Schnabel R., and Blankenberg S. Oxidative stress in cardiovascular disease. Successful translation from bench to bedside?. Circulation 116 (2007) 1338-1340